Resources from the same session
5276 - ESMO-MCBS and Health Technology Assessment (HTA): Does value for physicians correspond to value for payers?
Presenter: Apoorva Ambavane
Session: Proffered Paper - Public policy
Resources:
Abstract
Slides
Webcast
2243 - Change in Magnitude of Clinical Benefit, Overall Survival (OS) and Quality of Life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015.
Presenter: Aida Bujosa Rodríguez
Session: Proffered Paper - Public policy
Resources:
Abstract
Slides
Webcast
5379 - Consistency of ESMO-MCBS scores with drug access recommendations in Catalonia
Presenter: Mercè Obach
Session: Proffered Paper - Public policy
Resources:
Abstract
Slides
Webcast
5174 - The price of added value for new anti-cancer drugs in France 2004-17
Presenter: Patricia Marino
Session: Proffered Paper - Public policy
Resources:
Abstract
3815 - Reimbursement Reality for Off-label use in cancer care – A systematic empirical investigation
Presenter: Amanda Herbrand
Session: Proffered Paper - Public policy
Resources:
Abstract
Slides
Webcast
Proffered Paper - Public policy - Invited Discussant 1629O_PR and 1630O
Presenter: Bengt Jönsson
Session: Proffered Paper - Public policy
Resources:
Slides
Webcast